Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration

doi:10.12998/wjcc.v10.i13.3989

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4451)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-9) series, Tables (1-4) series.

Item

Count

PDF

262

WORD

HTML

2368

Figures (1-9)

381

Tables (1-4)

332

Sum=3403

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

333

Download

715

Sum=1048

May 6, 2022 (publication date) through Feb 14, 2025

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical and Translational Research

World J Clin Cases. May 6, 2022; 10(13): 3989-4019
Published online May 6, 2022. doi: 10.12998/wjcc.v10.i13.3989

Table 1 Clinical information description of hepatocellular carcinoma patients in The Cancer Genome Atlas

Description	Samples, n = 371	Percentage
Sex
Male	249	67.11
Female	121	32.61
Others	1	0.27
Race
White	184	49.60
Asian	158	42.59
Black or African American	16	4.31
Others	13	3.50
Vital status
Alive	240	64.69
Dead	130	35.14
Others	1	0.27
Age at diagnosis
≥ 60-years-old	197	53.10
< 60-years-old	169	45.55
Others	5	1.35
AJCC pathologic T
T1	180	48.52
T2	92	24.80
T2a	1	0.27
T2b	1	0.27
T3	45	12.13
T3a	29	7.82
T3b	6	1.62
T4	13	3.50
TX	1	0.27
Others	1	0.27
AJCC system for tumor staging
N0	239	64.42
N1	4	1.08
Nx	91	24.53
Others	2	0.54
AJCC system for metastasis staging
M0	265	71.43
M1	4	1.08
Mx	101	27.22
Others	1	0.27
AJCC system for stage
Stage I	170	45.82
Stage II	86	23.18
Stage III	3	0.81
Stage IIIA	65	17.52
Stage IIIB	8	2.16
Stage IIIC	9	2.43
Stage IV	2	0.54
Stage IVA	1	0.27
Stage IVB	2	0.54
Others	25	6.74
Prior malignancy
Yes	35	9.43
No	335	90.30
Others	1	0.27
Treatment or therapy
Yes	38	10.24
No	309	83.28
Others	24	6.47

AJCC: American Joint Committee on Cancer.

Table 2 Correlation of solute carrier family 2 member 1 and solute carrier family 2 expression and clinical prognosis in hepatocellular carcinoma with different clinicopathological factors in Kaplan-Meier plotter

Clinicopathological characteristics	Solute carrier family 2 member 1						Solute carrier family 2 member 2
	Overall survival			Relapse-free survival			Overall survival			Relapse-free survival
	n	Hazard ratio	P value	n	Hazard ratio	P value	n	Hazard ratio	P value	n	Hazard ratio	P value
Sex
Male	246	2.71 (1.73-4.24)	5.40E-06	210	1.36 (0.89-2.08)	0.149	246	0.3 (0.0.19-0.48)	5.80E-08	210	0.5 (0.34-0.75)	0.00068
Female	118	1.89 (1.06-3.38)	0.0287	106	1.61 (0.89-2.9)	0.1109	118	1.48 (0.75-2.93)	0.26	106	0.47 (0.26-0.85)	0.0108
Race
Asian	155	3.14 (1.71-5.77)	1.00E-04	143	1.54 (0.93-2.56)	0.092	155	0.2 (0.11-0.38)	3.80E-08	143	0.41 (0.23-0.73)	0.0017
White	181	1.98 (1.24-3.16)	0.0034	147	1.41 (0.88-2.27)	0.1527	181	0.61 (0.35-1.05)	0.072	147	0.53 (0.33-0.84)	0.0065
Black or African American	17	NA	NA	13	NA	NA	17	NA	NA	13	NA	NA
Sorafenib treatment
Yes	29	2.19 (0.61-7.89)	0.219	22	1.43 (0.59-3.47)	0.4312	29	0.23 (0.06-0.88)	0.0205	22	0.61 (0.24-1.53)	0.2867
None	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Risk factors
Alcohol consumption
Yes	115	1.94 (1-3.78)	0.0464	99	1.61 (0.86-3.03)	0.1365	115	0.42 (0.22-0.8)	0.0063	99	0.37 (0.2-0.67)	0.00061
None	202	2.34 (1.46-3.73)	0.00025	183	1.42 (0.9-2.23)	0.1284	202	0.41 (0.26-0.65)	9.70E-05	183	0.57 (0.34-0.96)	0.0337
Hepatitis virus
Yes	150	2.99 (1.5-5.95)	0.0011	139	1.45 (0.87-2.39)	0.149	150	0.32 (0.16-0.62)	0.0004	139	0.63 (0.37-1.05)	0.0749
None	167	2.39 (1.45-3.96)	0.00046	143	1.92 (1.12-3.32)	0.0168	167	0.47 (0.27-0.83)	0.0083	143	0.41 (0.25-0.68)	0.00038
Pathology
Stage
1	170	2.49 (1.33-4.64)	0.0031	153	1.67 (0.97-2.89)	0.0617	170	0.42 (0.22-0.77)	0.0044	153	0.41 (0.22-0.76)	0.0035
1+2	253	2.09 (1.27-3.44)	0.003	228	1.22 (0.8-1.86)	0.35	253	0.54 (0.33-0.87)	0.0107	228	0.4 (0.23-0.7)	0.00091
2	83	2.12 (0.79-5.64)	0.1258	75	0.5 (0.25-0.99)	0.0424	83	0.34 (0.1-1.14)	0.0665	75	0.56 (0.27-1.14)	0.1046
2+3	166	2.27 (1.39-3.7)	0.00072	145	1.44 (0.89-2.35)	0.1389	166	0.47 (0.26-0.83)	0.0077	145	0.65 (0.41-1.03)	0.064
3	83	2.78 (1.52-5.06)	0.00052	70	2.29 (1.21-4.3)	0.0086	83	0.31 (0.16-0.57)	0.00011	70	0.54 (0.29-0.99)	0.0428
3+4	87	2.67 (1.49-4.78)	6.00E-01	70	2.29 (1.21-4.3)	0.0086	87	0.34 (0.19-0.62)	0.0003	70	0.54 (0.29-0.99)	0.0428
4	5	NA	NA	0	NA	NA	4	NA	NA	0	NA	NA
Grade
1	55	0.67 (0.26-1.7)	0.3967	45	3.65 (0.83-16.1)	0.067	55	0.42 (0.14-1.27)	0.1114	45	0.45 (0.17-1.17)	0.0919
2	174	2.16 (1.29-3.61)	0.0025	149	1.49 (0.89-2.5)	0.1246	174	0.48 (0.28-0.81)	0.0051	149	0.48 (0.29-0.78)	0.0029
3	118	3.11 (1.69-5.7)	0.00012	107	2.16 (1.2-3.86)	0.0082	118	0.3 (0.14-0.66)	0.0014	107	0.62 (0.34-1,.14)	0.1221
4	12	NA	NA	11	NA	NA	12	NA	NA	11	NA	NA
American Joint Committee on Cancer system for tumor staging
1	180	2.31 (1.27-4.21)	0.0047	160	1.51 (0.89-2.58	0.1245	180	0.39 (0.22-0.71)	0.0014	160	0.41 (0.22-0.75)	0.0027
2	90	2.07 (0.79-5.44)	0.1303	80	0.48 (0.25-0.92)	0.023	90	0.45 (0.16-1.29)	0.1272	80	2.02 (0.9-4.56)	0.0836
3	78	3.04 (1.64-5.64)	0.00022	67	2.23 (1.11-4.48)	0.0209	78	0.29 (0.15-0.57)	0.00011	67	0.43 (0.22-0.83)	0.01
4	13	NA	NA	6	NA	NA	13	NA	NA	6	NA	NA
Vascular invasion
None	203	2.18 (91.26-3.78)	0.0043	175	1.32 (0.77-2.28)	0.3144	203	0.39 (0.23-0.66)	0.00027	175	0.45 (0.25-0.83)	0.0089
Micro	90	2.16 (1.01-4.62)	0.042	82	0.46 (0.24-0.88)	0.0163	90	0.32 (0.1-1.08)	0.0531	82	0.73 (0.37-1.44)	0.3593
Macro	16	NA	NA	14	NA	NA	16	NA	NA	14	NA	NA

NA: Not applicable.

Table 3 Correlation analysis between solute carrier family 2 member 1 and solute carrier family 2 and genes markers of immune cells in tumor immune estimation resource

Description	Gene markers	Solute carrier family 2 member 1				Solute carrier family 2 member 2
		None		Purity		None		Purity
		cor	P value	cor	P value	cor	P value	cor	P value
CD8+ T cell
	CD8A	0.216	2.88E-05	0.173	1.27E-03	-0.103	4.85E-02	-0.027	6.15E-01
	CD8B	0.229	8.60E-06	0.195	2.72E-04	-0.199	1.14E-04	-0.138	1.04E-02
T cell (general)
	CD3D	0.241	2.75E-06	0.22	3.73E-05	-0.327	1.33E-10	-0.276	1.88E-07
	CD3E	0.201	1.01E-04	0.162	2.59E-03	-0.165	1.44E-03	-0.087	1.08E-01
	CD2	0.178	5.64E-04	0.138	1.04E-02	-0.194	1.75E-04	-0.121	2.48E-02
B cell
	CD19	0.208	5.50E-05	0.176	1.04E-03	-0.137	8.06E-03	-0.089	9.95E-02
	CD79A	0.099	5.72E-02	0.045	4.01E-01	-0.138	7.84-03	-0.07	1.92E-01
Monocyte
	CD86	0.413	0.00E+00	0.415	8.08E-16	-0.196	1.50E-04	-0.15	5.21E-03
	CD115 (CSF1R)	0.41	0.00E+00	0.408	3.06E-15	-0.175	7.02E-04	-0.126	1.96E-02
Tumor-associated macrophage
	CCL2	0.206	6.86E-05	0.162	2.53E-03	-0.117	2.47E-02	-0.042	4.32E-01
	CD68	0.38	4.24E-14	0.381	2.40E-13	-0.235	5.28E-06	-0.192	3.26E-04
	IL10	0.326	1.26E-10	0.309	4.43E-09	-0.131	1.15E-02	-0.078	1.48E-01
M1 macrophage
	INOS (NOS2)	0.068	1.91E-01	0.052	3.39E-01	0.175	7.12E-04	0.18	7.95E-04
	IRF5	0.142	6.33E-03	0.138	1.05E-02	0.011	8.39E-01	0.003	9.63E-01
	COX2 (PTGS2)	0.32	2.91E-10	0.313	2.80E-09	-0.06	2.45E-01	-0.007	9.03E-01
M2 macrophage
	CD163	0.28	3.94E-08	0.253	1.91E-06	0.046	3.72E-01	0.125	2.00E-02
	VSIG4	0.353	3.65E-12	0.336	1.56E-10	-0.06	2.46E-01	-0.007	8.96E-01
	MS4A4A	0.337	3.49E-11	0.33	3.15E-10	-0.057	2.69E-01	0.01	9.85E-01
	CD66b (CEACAM8)	0.086	9.68E-02	0.084	1.20E-01	-0.036	4.89E-01	-0.027	6.12E-01
	CD11b (ITGAM)	0.428	0.00E+00	0.405	4.71E-15	-0.18	5.06E-04	-0.156	3.75E-03
	CCR7	0.088	8.89E-02	0.016	7.70E-01	-0.032	5.35E-01	-0.045	4.00E-01
	KIR2DL1	0.083	1.09E-01	0.063	2.46E-01	-0.003	9.51E-01	0.019	7.23E-01
	KIR2DL3	0.179	5.16E-04	0.167	1.82E-03	-0.006	9.15E-01	-0.038	4.79E-01
	KIR2DL4	0.234	5.38E-06	0.212	7.12E-05	-0.133	1.06E-02	-0.107	4.78E-02
	KIR3DL1	0.146	4.97E-03	0.12	2.64E-02	0.079	1.30E-01	0.116	3.15E-02
	KIR3DL2	0.098	6.04E-02	0.08	1.38E-01	-0.027	6.02E-01	0.003	9.60E-01
	KIR3DL3	0.06	2.53E-01	0.046	3.91E-01	-0.021	6.91E-01	-0.015	7.87E-01
	KIR2DS4	0.117	2.39E-02	0.13	1.57E-02	0.04	4.37E-01	0.052	3.37E-01
	HLA-DPB1	0.319	4.21E-10	0.296	2.07E-08	-0.191	2.25E-04	-0.138	1.03E-02
	HLA-DQB1	0.221	1.77E-05	0.192	3.35E-04	-0.219	2.09E-05	-0.171	1.43E-03
	HLA-DRA	0.35	5.25E-12	0.326	5.24E-10	-0.117	2.37E-02	-0.055	3.09E-01
	HLA-DPA1	0.338	3.01E-11	0.316	1.92E-09	-0.114	2.88E-02	-0.052	3.34E-01
	BDCA-1 (CD1C)	0.061	2.45E-01	0.024	6.52E-01	0.004	9.40E-01	0.073	1.77E-01
	BDCA-4 (NRP1)	0.357	1.99E-12	0.352	1.70E-11	0.043	4.13E-01	0.087	1.08E-01
	CD11c (ITGAX)	0.382	2.93E-14	0.38	2.50E-13	-0.154	2.93E-03	-0.118	2.86E-02
Th1
	T-bet (TBX21)	0.095	6.88E-02	0.042	4.32E-01	0.025	6.38E-01	0.116	3.07E-02
	STAT4	0.082	1.13E-01	0.045	4.04E-01	-0.106	4.22E-02	-0.058	2.84E-01
	STAT1	0.314	7.29E-10	0.29	4.18E-08	0.023	6.52E-01	0.058	2.84E-01
	IFN-γ (IFNG)	0.237	3.81E-06	0.212	7.39E-05	-0.169	1.09E-03	-0.122	2.31E-02
	TNF-α (TNF)	0.277	6.15E-08	0.257	1.34E-06	-0.147	4.67E-03	-0.092	8.91E-02
Th2
	GATA3	0.248	1.34E-06	0.235	1.03E-05	-0.176	6.76E-04	-0.108	4.52E-02
	STAT6	0.27	1.35E-07	0.255	1.63E-06	0.178	5.68E-04	0.19	3.82E-04
	STAT5A	0.37	1.83E-13	0.338	1.18E-10	-0.097	6.27E-02	-0.055	3.12E-01
	IL13	-0.081	1.19E-01	-0.113	3.56E-02	0.077	1.38E-01	0.09	9.40E-02
Tfh
	BCL6	0.267	2.04E-07	0.281	1.16E-07	0.227	1.08E-05	0.228	1.94E-05
	IL21	0.124	1.65E-02	0.13	1.55E-02	-0.065	2.15E-01	-0.06	2.68E-01
Th17
	IL17A	-0.047	3.68E-01	-0.033	5.46E-01	0.04	4.47E-01	-0.051	3.41E-01
T cell regulatory
	FOXP3	0.068	1.89E-01	-0.039	4.68E-01	0.169	1.07E-03	0.189	4.24E-04
	CCR8	0.286	1.95E-08	0.264	6.44E-07	-0.056	2.79E-01	-0.008	8.86E-01
	STAT5B	0.156	2.63E-03	0.173	1.29E-03	0.402	0.00E+00	0.397	1.83E-14
	TGFβ (TGFB1)	0.314	7.92E-10	0.303	8.83E-09	-0.281	4.30E-08	-0.242	5.53E-06
T cell exhaustion
	PD-1 (PDCD1)	0.256	5.91E-07	0.232	1.31E-05	-0.281	3.50E-08	-0.238	7.71E-06
	CTLA4	0.284	2.57E-08	0.266	5.31E-07	-0.327	1.15E-10	-0.283	8.93E-08
	LAG3	0.156	2.67E-02	0.127	1.83E-02	-0.195	1.66E-04	-0.165	2.15E-03
	TIM-3 (HAVCR2)	0.434	0.00E+00	0.437	1.52E-17	-0.255	6.91E-07	-0.228	1.89E-05
	GZMB	0.176	6.91E-04	0.131	1.51E-02	-0.124	1.70E-02	-0.068	2.10E-01

cor: Correlation coefficient; L10: Interleukin 10; INOS: Nitric oxide synthase 2; IRF5: Interferon regulatory factor 5; COX2: Cytochrome c oxidase subunit II; VSIG4: V-set and immunoglobulin domain containing 4; MS4A4A: Membrane spanning 4-domains A4A; CCR7: C-C motif chemokine receptor 7; KIR2DL1: Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1; KIR2DL3: Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3; KIR2DL4: Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4; KIR3DL1: Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1; KIR3DL2: Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2; KIR3DL3: Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 3; KIR2DS4: Killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 4; HLA-DPB1: Major histocompatibility complex, class II, DP beta 1; HLA-DQB1: Major histocompatibility complex, class II, DQ beta 1; HLA-DRA: Major histocompatibility complex, class II, DR alpha; HLA-DPA1: Major histocompatibility complex, class II, DP alpha 1; BDCA-4: Neuropilin 1; T-bet: T-box transcription factor 21; STAT4: Signal transducer and activator of transcription 4; STAT1: Signal transducer and activator of transcription 1; IFN-γ: Interferon gamma; TNF-α: Tumor necrosis factor; GATA3: GATA binding protein 3; STAT6: Signal transducer and activator of transcription 6; STAT5A: Signal transducer and activator of transcription 5A; IL13: Interleukin 13; BCL6: BCL6 transcription repressor; IL21: Interleukin 21; IL17A: Interleukin 17A; FOXP3: Forkhead box P3; CCR8: C-C motif chemokine receptor 8; STAT5B: Signal transducer and activator of transcription 5B; TGFβ: Transforming growth factor-beta; PD-1: Programmed cell death 1; CTLA4: Cytotoxic T-lymphocyte associated protein 4; LAG3: Lymphocyte activating 3; TIM-3: Hepatitis A virus cellular receptor 2; GZMB: Granzyme B; Tfh: Follicular helper T.

Table 4 Correlation analysis between solute carrier family 2 member 1 and solute carrier family 2 and genes markers of immune cells in gene expression profiling interactive analysis

Description	Gene markers	Solute carrier family 2 member 1		Solute carrier family 2 member 2
Description	Gene markers	cor	P value	cor	P value
CD8+ T cell
	CD8A	0.24	3.10E-06	-0.084	1.10E-01
	CD8B	0.26	3.20E-07	-0.13	1.40E-02
T cell (general)
	CD3D	0.18	5.10E-04	-0.23	1.10E-05
	CD3E	0.15	4.00E-03	-0.11	3.90E-02
	CD2	0.17	1.50E-03	-0.12	2.60E-02
B cell
	CD19	0.22	1.60E-05	-0.073	1.60E-01
	CD79A	0.036	4.90E-01	-0.59	2.60E-01
Monocyte
	CD86	0.39	1.50E-14	-0.16	1.70E-03
	CD115 (CSF1R)	0.36	1.40E-12	-0.14	5.40E-03
Tumor-associated macrophage
	CCL2	0.16	2.30E-03	-0.13	1.50E-02
	CD68	0.27	9.20E-08	-0.14	6.50E-03
	IL10	0.32	2.50E-10	-0.095	6.70E-02
M1 macrophage
	INOS (NOS2)	-0.031	5.50E-01	0.2	1.20E-04
	IRF5	0.14	7.40E-03	0.044	4.00E-01
	COX2 (PTGS2)	0.16	1.50E-03	-0.028	5.90E-01
M2 macrophage
	CD163	0.31	7.00E-10	-0.13	1.40E-02
	VSIG4	0.36	1.10E-12	-0.12	1.80E-02
	MS4A4A	0.29	1.50E-08	-0.11	2.80E-02
	CD66b (CEACAM8)	0.074	1.60E-01	-0.018	7.30E-01
Neutrophil
	CD11b (ITGAM)	0.28	5.80E-08	-0.074	1.60E-01
	CCR7	0.039	4.60E-01	-0.028	5.90E-01
Natural killer cell
	KIR2DL1	0.087	9.40E-02	-0.059	2.60E-01
	KIR2DL3	0.13	1.40E-02	-0.05	3.40E-01
	KIR2DL4	0.18	7.10E-04	-0.12	2.00E-02
	KIR3DL1	0.086	9.70E-02	-0.058	2.70E-01
	KIR3DL2	0.069	1.90E-01	-0.0081	8.80E-01
	KIR3DL3	0.08	1.30E-01	-0.068	1.90E-01
	KIR2DS4	0.044	4.00E-01	0.02	7.10E-01
Dendritic cell
	HLA-DPB1	0.25	1.40E-06	-0.16	2.20E-03
	HLA-DQB1	0.14	8.10E-03	-0.19	2.60E-04
	HLA-DRA	0.26	6.00E-07	-0.15	5.00E-03
	HLA-DPA1	0.2	8.00E-05	-0.12	2.30E-02
	BDCA-1 (CD1C)	0.12	2.40E-02	-0.044	4.00E-01
	BDCA-4 (NRP1)	0.23	6.80E-06	-0.037	4.80E-01
	CD11c (ITGAX)	0.24	2.00E-06	-0.13	1.40E-02
Th1
	T-bet (TBX21)	0.088	9.00E-02	-0.058	2.70E-01
	STAT4	0.0027	9.60E-01	-0.041	4.40E-01
	STAT1	0.13	1.10E-02	0.017	7.50E-01
	IFN-γ (IFNG)	0.19	3.30E-04	-0.1	4.70E-02
	TNF-α (TNF)	0.12	2.00E-02	-0.1	5.40E-02
Th2
	GATA3	0.31	2.10E-09	-0.13	1.20E-02
	STAT6	0.15	4.80E-03	0.19	2.40E-04
	STAT5A	0.2	8.20E-05	-0.07	1.80E-01
	IL13	-0.025	6.30E-01	-0.01	8.40E-01
Tfh
	BCL6	0.1	4.70E-02	0.24	2.70E-06
	IL21	0.072	1.70E-01	-0.044	3.90E-01
Th17
	IL17A	-0.022	6.70E-01	0.071	1.80E-01
T cell regulatory
	FOXP3	-0.036	4.90E-01	0.17	1.40E-03
	CCR8	0.16	1.90E-03	-0.082	1.20E-01
	STAT5B	0.073	1.60E-01	0.43	0.00E+00
	TGFβ (TGFB1)	0.24	2.10E-06	-0.25	1.40E-06
T cell exhaustion
	PD-1 (PDCD1)	0.08	1.20E-01	-0.12	2.00E-02
	CTLA4	0.17	1.10E-03	-0.18	7.20E-04
	LAG3	0.23	7.60E-06	-0.19	3.30E-04
	TIM-3 (HAVCR2)	0.22	1.30E-05	-0.17	1.30E-03
	GZMB	0.17	8.10E-04	-0.16	2.20E-03

cor: Correlation coefficient; L10: Interleukin 10; INOS: Nitric oxide synthase 2; IRF5: Interferon regulatory factor 5; COX2: Cytochrome c oxidase subunit II; VSIG4: V-set and immunoglobulin domain containing 4; MS4A4A: Membrane spanning 4-domains A4A; CCR7: C-C motif chemokine receptor 7; KIR2DL1: Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1; KIR2DL3: Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3; KIR2DL4: Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4; KIR3DL1: Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1; KIR3DL2: Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2; KIR3DL3: Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 3; KIR2DS4: Killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 4; HLA-DPB1: Major histocompatibility complex, class II, DP beta 1; HLA-DQB1: Major histocompatibility complex, class II, DQ beta 1; HLA-DRA: Major histocompatibility complex, class II, DR alpha; HLA-DPA1: Major histocompatibility complex, class II, DP alpha 1; BDCA-4: Neuropilin 1; T-bet: T-box transcription factor 21; STAT4: Signal transducer and activator of transcription 4; STAT1: Signal transducer and activator of transcription 1; IFN-γ: Interferon gamma; TNF-α: Tumor necrosis factor; GATA3: GATA Binding protein 3; STAT6: Signal transducer and activator of transcription 6; STAT5A: Signal transducer and activator of transcription 5A; IL13: Interleukin 13; BCL6: BCL6 transcription repressor; IL21: Interleukin 21; IL17A: Interleukin 17A; FOXP3: Forkhead box P3; CCR8: C-C motif chemokine receptor 8; STAT5B: Signal transducer and activator of transcription 5B; TGFβ: Transforming growth factor-beta; PD-1: Programmed cell death 1; CTLA4: Cytotoxic T-lymphocyte associated protein 4; LAG3: Lymphocyte activating 3; TIM-3: Hepatitis A virus cellular receptor 2; GZMB: Granzyme B; Th: T helper; Tfh: Follicular helper T.

Citation: Peng Q, Hao LY, Guo YL, Zhang ZQ, Ji JM, Xue Y, Liu YW, Lu JL, Li CG, Shi XL. Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration. World J Clin Cases 2022; 10(13): 3989-4019
URL: https://www.wjgnet.com/2307-8960/full/v10/i13/3989.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i13.3989